- $24.42m
- $16.00m
- $3.02m
TherapeuticsMD Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Therapeuticsmd Announces Issuance Of A J-Code For Annovera® To Be Utilized In The Public Health Sector
Brief: Therapeuticsmd Announces Appointment Of Hugh O’Dowd As President
TherapeuticsMD Inc reports results for the quarter ended in June - Earnings Summary
Brief: TherapeuticsMD Says Net Loss For Q2 2021 Was $0.11 Per Basic And Diluted Share
Brief: Therapeuticsmd Announces Submission Of Low Dose Bijuva® 0.5 Mg/100 Mg Supplemental New Drug Application To FDA
TherapeuticsMD Inc reports results for the quarter ended in March - Earnings Summary
Brief: Therapeuticsmd Reports Q1 Revenue $19.9 mln
TherapeuticsMD Inc expected to post a loss of 12 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Boeing, Alibaba Group, Bioceres, Tenax Therapeutics
U.S. STOCKS ON THE MOVE-Celcuity Inc, Affimed, Sogou Inc, Lucira Health
U.S. STOCKS ON THE MOVE-Provention Bio, fuboTV, Medalist, Global Ship Lease
TherapeuticsMD: Jumps after UK, Belgium approve hormone therapy
Brief: TherapeuticsMD And Theramex Announce Approval Of Bijuve Capsules For Hormone Replacement Therapy In UK And Belgium
Brief: TherapeuticsMD Reports Q4 And Full Year 2020 Results
Brief: TherapeuticsMD Announces Pricing Of $110 Mln Public Offering Of Common Stock
Brief: TherapeuticsMD Announces Underwritten Public Offering Of Its Common Stock
U.S. RESEARCH ROUNDUP- American Woodmark, Comtech Telecommunications, Mohawk Group Holdings
Brief: TherapeuticsMD Says Entered Into Sales Agreement With Cantor Fitzgerald & Co, Pursuant To Which Co May Offer And Sell Shares Of Up To $50.0 Mln